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Background
There is striking paucity of a rigorous evidence-base for
the treatment of paediatric musculoskeletal diseases. The
Medicines for Children Research Network (MCRN)
improves coordination and quality of clinical trials and
related studies across the UK. It has joined in partnership
with the Arthritis Research Campaign (arc), the major UK
charitable funder of musculoskeletal research, to form the
MCRN/arc Paediatric Rheumatology CSG.
Methods
The MCRN has extensive expertise in supporting non-
commercial, pharmaceutical-sponsored and investigator-
led studies. The CSG is a multi-disciplinary group com-
prising clinicians, academics, basic scientist, pharmacy,
and clinical trials unit support. Through consultation with
stakeholders, its remit includes: developing a comprehen-
sive portfolio for clinical trials/related studies covering the
spectrum of paediatric rheumatology; ensuring consumer
involvement; upholding Good Clinical Practice.
Results
The CSG has developed topic-specific groups (TSGs) out-
lined in Table 1. Key "themes" across TSGs include:
acceptability of intervention; quality of life; health eco-
nomics; cardiovascular risk; skeletal health; rare diseases;
orphan drugs; international collaboration. Key "tools"
include: characterised phenotype cohort studies; biomar-
kers; genotype/phenotype/proteomics; pharmacogenom-
ics; pharmacokinetic studies; mechanism of disease;
Phase II and III studies. Strategic development of proto-
cols is underway. Regionally based networks assist with
feasibility, site selection, financial, ethical and governance
arrangements, staff recruitment, training, participant
recruitment and trial monitoring. Table 2 illustrates stud-
ies already MCRN adopted and supported in this way.
Conclusion
An integrated national research network provides an
excellent infrastructure to collaborate closely with interna-
tional trial networks (e.g. CARRA, PRINTO) while foster-
ing a unique contribution to the transformation of clinical
care of children.
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Juvenile idiopathic arthritis (JIA)
Juvenile-onset SLE
Rare disorders (Initial focus on Scleroderma)
Uveitis in JIA
Vasculitis
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Table 2: Studies recently adopted by MCRN
Acronym Study Title
POPS Study Prevention and treatment of steriod-induced osteopaenia in children and adolescents with rheumatic 
diseases
UK JSLE Cohort Study and Repository UK Juvenile-onset Systemic Lupus Erythematosis Cohort Study epository: Clinical Characteristics and 
Immunopathology of Juvenile-onset SLE
MYCYC A randomised clinical trial of mycophenolate mofetil versus cyclophosphamide for remission induction in 
ANCA associated vasculitis
SPARKS CHARMS A study of the immunological and genetic mechanisms of response, and psychological response to, 
standard disease management in juvenile idiopathic arthritis (JIA)Page 2 of 2
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